Platinum Investment Management Ltd. Invests $1.56 Million in Palisade Bio, Inc. $PALI

Platinum Investment Management Ltd. acquired a new stake in Palisade Bio, Inc. (NASDAQ:PALI) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 664,087 shares of the company’s stock, valued at approximately $1,561,000. Platinum Investment Management Ltd. owned about 0.45% of Palisade Bio as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of PALI. Franklin Resources Inc. acquired a new stake in shares of Palisade Bio during the fourth quarter worth $11,968,000. Renaissance Technologies LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth $5,599,000. Geode Capital Management LLC increased its position in shares of Palisade Bio by 5,780.7% during the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock worth $3,681,000 after buying an additional 1,538,832 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Palisade Bio during the fourth quarter worth $1,310,000. Finally, Jane Street Group LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth $808,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PALI has been the subject of several recent analyst reports. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Wolfe Research began coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective for the company. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. HC Wainwright started coverage on Palisade Bio in a report on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price for the company. Finally, Stifel Nicolaus started coverage on Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.20.

Palisade Bio Stock Performance

Shares of PALI stock opened at $1.71 on Friday. The company has a market cap of $296.82 million, a P/E ratio of -1.69 and a beta of 1.52. The stock has a 50 day simple moving average of $1.98 and a two-hundred day simple moving average of $1.92. Palisade Bio, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.86.

Palisade Bio (NASDAQ:PALI) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, research analysts predict that Palisade Bio, Inc. will post -0.21 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.